Micro-UltraSound In Cancer - Active Surveillance
Launched by UNIVERSITY OF ALBERTA · Sep 23, 2022
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different imaging techniques, MRI and micro-ultrasound, to see which one is better at detecting significant prostate cancer in men who are being closely monitored, known as Active Surveillance. The trial involves taking samples from the prostate using both methods to compare their effectiveness in finding potentially serious cancer. Additionally, blood samples will be collected for future studies that may help improve cancer detection and treatment.
To be eligible for this trial, men must be between 65 and 74 years old and have a specific early-stage prostate cancer called Gleason Grade Group 1. They should also need a confirmatory biopsy to check their cancer status. It's important to note that men who cannot have an MRI or a biopsy are not eligible. If you decide to participate, you will undergo imaging and biopsies as part of the study, which may help improve how prostate cancer is monitored and treated in the future.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Adult men with Gleason Grade Group 1 prostate cancer managed by active surveillance who require a confirmatory prostate biopsy
- Exclusion Criteria:
- • Men who cannot undergo a prostate MRI
- • Men who cannot undergo a prostate biopsy
About University Of Alberta
The University of Alberta, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong commitment to scientific excellence and community health, the university facilitates cutting-edge research across various medical disciplines. Its interdisciplinary approach fosters collaboration among researchers, clinicians, and students, ensuring that clinical trials are designed and conducted with the utmost rigor and ethical standards. By leveraging its extensive resources and expertise, the University of Alberta aims to translate research findings into meaningful advancements in patient care and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Los Angeles, California, United States
Vancouver, Alberta, Canada
Montreal, Quebec, Canada
Patients applied
Trial Officials
Adam Kinnaird, MD, PhD
Principal Investigator
University of Alberta
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials